Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Vitamin and mineral supplement use high among U.S. children and teens

A large number of U.S. children and teens age 2 to 17 appear to use vitamin and mineral supplements, although most may not need them, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

2 Feb 2009

Salmonella prompts recall of Kellogg's snacks

Food and Drug Administration (FDA) officials in the United States have confirmed the presence of salmonella in a popular snack made by food giant Kellogg.

19 Jan 2009

Discovery of gene that increases susceptibility to Crohn's disease

Researchers at McGill University, the Research Institute of the McGill University Health Centre (RI MUHC) and the McGill University and Génome Québec Innovation Centre, along with colleagues at other Canadian and Belgian institutions, have discovered DNA variations in a gene that increases susceptibility to developing Crohn's disease.

8 Jan 2009

New genetic markers for ulcerative colitis could lead to treatment

An international consortium of researchers, including major contribution from a team led by Dr. John D. Rioux, a professor of medicine at the Université de Montréal and the Montreal Heart Institute, has identified genetic markers associated with risk for ulcerative colitis.

8 Jan 2009

Discovery of new genetic markers for ulcerative colitis

An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis.

5 Jan 2009

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).

1 Jan 2009

Medication errors among adults and children with cancer in the outpatient setting common

Seven percent of adults and 19 percent of children taking chemotherapy drugs in outpatient clinics or at home were given the wrong dose or experienced other mistakes involving their medications, according to a new study supported in part by HHS' Agency for Healthcare Research and Quality through its Centers for Education and Research on Therapeutics program.

1 Jan 2009

Antioxidant supplementation effective in relieving pain in chronic pancreatitis

Antioxidant supplementation was found to be effective in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis (CP), reports a new study in Gastroenterology.

1 Jan 2009

New screening test for chronic abdominal pain

Evaluation of chronic abdominal pain of luminal etiology is a challenging problem for the primary care physicians and gastroenterologists.

30 Dec 2008

AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium)

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old.

21 Dec 2008

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

The U.S. Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication – keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

21 Dec 2008

Updated guidelines for irritable bowel syndrome

Although irritable bowel syndrome (IBS) is the most common disease diagnosed by gastroenterologists, it's also one of the most misunderstood.

18 Dec 2008

Expert says gross over-reaction to peanuts to blame for 'nut hysteria'

A Professor at Harvard Medical School suggests many people today are over-reacting to the threat of peanut allergies in children.

17 Dec 2008

Magnets in toys pose serious health risks

While the danger of magnets for children is increasingly recognized, they don't receive treatment for swallowing them as quickly as needed, and parents don't receive sufficient warning on toys, according to a new study.

10 Dec 2008

Merck Serono's Kuvan receives European marketing authorization

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.

10 Dec 2008

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.

8 Dec 2008

Alarm over high lead contamination of Esperance sea food

Alarm over high lead contamination of Esperance sea food. The presence of high concentrations of lead found in fish in a part of Western Australia has prompted a warning to people living in the Esperance area to avoid eating some local seafood.

8 Dec 2008

FDA strengthens safety of Sucraid (sacrosidase) oral solution

The U.S. Food and Drug Administration today issued an expedited approval of a supplemental application that allows for changes in the manufacturing of Sucraid (sacrosidase) Oral Solution.

20 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008